

REMARKS

Applicants have amended the claims to more particularly point out and distinctly claim what they wish to prosecute in this application. Applicants have canceled claims 3, 5, 8 and 23, which would have been duplicative in view of the claim amendments.

Support for the amendments to claims 1, 7, 10, and 22 is found throughout the specification, e.g., at page 13, lines 3-10. Support for the ATCC deposit information in claims 1, 7, 10 and 22 is found, e.g., at page 1, lines 31-33. Claim 25 has been amended to improve its form. Support for these amendments is found throughout the specification, e.g., at page 50, line 10 to page 54, line 23. Claim 60 has been amended to correct a minor typographical error. None of the amendments adds new matter.

The Examiner states that restriction of the pending claims into one of the following four groups is required under 35 U.S.C. § 121:

- | | |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Group I | Claims 1-10, 22-23, 25-52 and 60-61, drawn to an isolated monoclonal antibody having an isotype that fixes complement and a variable region that binds to the epitope on CD147, method of making antibodies, a kit and a pharmaceutical composition; |
| Group II | Claims 11-15, drawn to a method to select anti-CD147 antibodies for the treatment of disease comprising generating antibodies that bind to CD147 and that are capable of binding complement, and assaying the antibodies; |

- Group III Claims 16-21 and 53-59, drawn to a method to treat disease with an antibody that has an isotype that fixes complement and a variable region that binds to CD147, wherein the disease is GVHD;
- Group IV Claim 24, drawn an isolated peptide.

The Examiner asserts that the inventions are distinct from each other, and states that applicant must elect one group of inventions for examination.

Applicants elect Group I, claims 1-10, 22-23, 25-52 and 60-61, without traverse. The Examiner has also required a species election if Group I is elected. Specifically, the Examiner states that the applicant is required to elect a single intact antibody from those recited in claims 60-61. Applicants provisionally elect the human antibody of claim 60, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:40 and wherein the light chain comprises the amino acid sequence of SEQ ID NO:41. Applicants' election is made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or in other applications claiming benefit herefrom.

Should the Examiner feel that a telephone conference with applicants' representatives would assist the Examiner, he is invited to telephone the undersigned at

Application No. 09/784,950
Response dated January 28, 2005
In Response to July 28, 2004 Restriction Requirement

anytime. Applicants request favorable consideration of the application and early allowance of the pending claims.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
R. Minako Pazdera (Reg. No. 46,984)
Agent for Applicants

FISH & NEAVE IP GROUP
ROPES & GRAY
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090